

Certificate of Analysis

NIGMS Human Genetic Cell Repository

Human induced Pluripotent Stem Cell (iPSC) Line: GM27102*B

Diagnosis	Isogenic Control, Cystic Fibrosis
Parental cell line mutation	CFTR; c.1521-1523delCTT (p.F508del) (mutation corrected with CRISPR/Cas9); c.1533C>A
Wild type Cell line, cell line ID	iPSC, GM24683
Sex	Male
Reprogramming method	Episomal vectors containing OCT3/4 with shp53, SOX2, KLF4, LMYC, and LIN28A
Passage number at freeze	P35
Culture media	DMEM/F12 + 20% KOSR + 10ng/ml FGF
Feeder or Matrix substrate	CF1 MEFs on 0.1% Gelatin
Recommended passage method and split ratio	Tryple Express; 1:6 every 3-5 days
iPSC line establishment publication(s)	

The following testing specifications have been met for this product lot:

Test Description	Test Method	Test Specification	Result
Post-Thaw Cell Viability	Colony doubling	Colony formation and diameter doubling within 5 days	Pass
Sterility	Growth on agar and broth Negative		Pass
Mycoplasma	qRT-PCR Negative		Pass
Alkaline Phosphatase Staining	Cell staining >80% cells with positive staining		Pass
Identity Match	STR (THO-1, D22S417, D10S526, vWA31, D5S592, and FES/FPS) Match parental cell line		Pass
Genomic Integration of Episomal Plasmid	Genomic PCR using plasmid specific primers and endogenous FBXO1 control No plasmid specific sequence amplified using 100 ng gDNA template		Pass
Detection of Sendai Virus Genome and Transgene	qRT-PCR using SEV specific primers	using SEV specific primers No detection of SEV genome or transgenes	
Surface Antigen Expression of Stem Cell Markers	Immunostaining and flow cytometric detection	on >80% expression of SSEA4	
Differentiation Potential	Embryoid body (EB) formation and gene expression Minimum of 1 gene per germ layer expressed 2 fold or higher		Pass
Cytogenomics	G-banding, Affymetrix Human SNP Array 6.0	uman SNP Array 6.0 46,XY[20].arr(1-22)x2,(X,Y)x1	

*Note:

Kenneth S. George 03/27/2020 Technician, Stem Cell Laboratory Date

Manager, Stem Cell Laboratory

Christine Grandizio

.....

Date

03/27/2020

Disclaimer: iPSC lines distributed by Coriell Institute for Medical Research may differ from one passage or expansion to another.

Form 1701-07 Rev P-110519: NIGMS HGCR Certificate of Analysis GM27102*B



Post-Thaw Cell Viability

One distribution lot vial of the cell line was thawed and placed in culture. Cultures were observed daily. Colonies were photographed upon first appearance, then 2 days later. Colonies must double in diameter within 5 days. The area for 5 colonies was measured using CellSens software on the Olympus IX50 microscope at 40x magnification. The average area is reported here.

Day	Average area (µm ²)
1	7,242
3	67,980

Colony area increased by 9 fold.




Figure 1A. Colonies post thaw (Day 1)




Figure 1B. Colonies 2 days after first observation (Day 3)

Alkaline Phosphatase Staining

Cells were stained using the StemTAG[™] Alkaline Phosphatase Staining Kit from CellBiolabs, Inc.





Figure 2. iPSC colonies showing alkaline phosphatase activity

Form 1701-07 Rev P-110519: NIGMS HGCR Certificate of Analysis GM27102*B



Surface Antigen Expression of Stem Cell Markers

Undifferentiated cells are stained for stage specific embryonic antigen 4 (SSEA4) which is expressed on the surface of undifferentiated human pluripotent stem cells. Cells were analyzed using the MACSQuant Flow Cytometer by Miltyeni Biotec. More than 80% of cells should stain with antibodies specific for SSEA4.



GM27102_B_SSEA 4_2020-01-22.0001\Live cells\Single Cells


Figure 3. Representative histogram of SSEA4 positive population showing an overlay of isotype stained control (red) and SSEA4 positive population (blue)

Form 1701-07 Rev P-110519: NIGMS HGCR Certificate of Analysis GM27102*B



Differentiation Potential

Cells are differentiated by embryoid body (EB) formation to assess pluripotency. RNA is extracted and gene expression is measured by quantitative RT-PCR. Ct values are adjusted to the endogenous housekeeping gene GAPDH. Relative gene expression is shown as the fold difference in expression compared to undifferentiated cells. Expression of at least one gene per germ layer should increase by 2 fold or higher.



Gene	Fold change	Gene	Fold change	Gene	Fold change	Gene	Fold change
OCT4	0	PAX6	0	Т	13	AFP	8652
SOX2	0	NES	0	RUNX1	4	SOX17	4
NANOG	0	TP63	0	DES	8	FOXA2	5
GDF3	0	KRT14	9	PECAM1	104	SOX7	19
REXO1	0	NOG	11	TAL1	100		

Figure 4. Fold change in expression of pluripotency genes and tri-lineage specific genes

Note: Negative values are set as 0. Calculations are performed using the $2^{-\Delta\Delta CT}$ method. (*Livak KJ, Schmittgen TD. Methods. 2001 Dec;25(4):402-8.PMID:11846609*)

Form 1701-07 Rev P-110519: NIGMS HGCR Certificate of Analysis GM27102*B



Cytogenomics

Microarray	Affymetrix Human SNP Array 6.0
Cytogenetic Banding Technique	G-banding
Passage at Analysis	P38
Metaphase Cells Counted	20
Metaphase Cells Analyzed	5
Metaphase Cells Karyotyped	5
Short ISCN	46,XY[20].arr(1-22)x2,(X,Y)x1




Figure 5. G-banding karyogram


Form 1701-07 Rev P-110519: NIGMS HGCR Certificate of Analysis GM27102*B




Sequence Verification

The presence of the *CFTR* c.1521-1523delCTT (p.F508del) deletion mutation in the patient-derived line (GM24683) was confirmed by Sanger sequencing of the *CFTR* gene. The corrected CRISPR-Cas9 geneedited mutation was also confirmed by Sanger sequencing. A resultant silent mutation (*CFTR* c.1533C>A) was also detected. The top five most likely off-target CRISPR-Cas9 cutting sites were also screened by Sanger sequencing and no off-target cutting was detected.

GM24683 – Cystic fibrosis (*CFTR*) c.1521-1523delCTT, p.F508del



GM27102 – Isogenic control for Cystic fibrosis (CFTR) Mutation corrected



Form 1701-07 Rev P-110519: NIGMS HGCR Certificate of Analysis GM27102*B